(MDT) Medtronic - NYSE
Sector: Healthcare | Industry: Medical Devices | Exchange: NYSE (USA) | Market Cap: 103.199m USD | Total Return: -5.2% in 12m
Avg Turnover: 887M
EPS Trend: 76.2%
Qual. Beats: 0
Rev. Trend: 97.3%
Qual. Beats: 4
Warnings
Below Avwap Earnings
Tailwinds
No distinct edge detected
Medtronic plc (NYSE: MDT) is a global medical device company founded in 1949 and headquartered in Galway, Ireland. It develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients across the United States, Ireland, and international markets.
The company operates through four main business segments: Cardiovascular Portfolio (offering pacemakers, defibrillators, cardiac ablation products, heart valves, and endovascular stent grafts), Neuroscience Portfolio (including spinal cord stimulation, brain modulation systems, drug infusion systems, and the Accurian nerve ablation system), Medical Surgical Portfolio (covering surgical stapling, robotic-assisted surgery, hernia devices, and patient monitoring products), and a Diabetes Operating Unit (providing insulin pumps, continuous glucose monitoring systems, and the InPen smart insulin pen).
Medtronic competes in the Health Care Equipment sub-industry within the broader Health Care sector, a space dominated by large multinational firms developing capital-intensive, regulated medical technologies. Its diversified portfolio spans chronic disease management, surgical solutions, and neuromodulation, with products sold across multiple medical specialties including cardiology, neurology, orthopedics, and endocrinology.
- MiniMed 780G adoption fuels Diabetes segment growth
- Hugo robot launches compete with Intuitive Surgical
- TAVR market share faces pressure from Edwards Lifesciences
| Net Income: 4.80b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 0.17 > 1.0 |
| NWC/Revenue: 40.08% < 20% (prev 31.82%; Δ 8.26% < -1%) |
| CFO/TA 0.08 > 3% & CFO 7.33b > Net Income 4.80b |
| Net Debt (27.0b) to EBITDA (9.43b): 2.86 < 3 |
| Current Ratio: 2.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.29b) vs 12m ago 0.16% < -2% |
| Gross Margin: 65.02% > 18% (prev 65.31%; Δ -0.30% > 0.5%) |
| Asset Turnover: 40.08% > 50% (prev 37.27%; Δ 2.81% > 0%) |
| Interest Coverage Ratio: 9.04 > 6 (EBIT TTM 6.47b / Interest Expense TTM 715.0m) |
| A: 0.16 (Total Current Assets 24.1b - Total Current Liabilities 9.49b) / Total Assets 91.5b |
| B: 0.35 (Retained Earnings 32.3b / Total Assets 91.5b) |
| C: 0.07 (EBIT TTM 6.47b / Avg Total Assets 90.7b) |
| D: 1.16 (Book Value of Equity 49.0b / Total Liabilities 42.3b) |
| Altman-Z'' = 3.89 = AA |
| DSRI: 0.10 (Receivables 87.0m/6.12b, Revenue 36.4b/33.5b) |
| GMI: 1.00 (GM 65.31% / 65.02%) |
| AQI: 0.98 (AQ_t 0.66 / AQ_t-1 0.68) |
| SGI: 1.08 (Revenue 36.4b / 33.5b) |
| TATA: -0.03 (NI 4.80b - CFO 7.33b) / TA 91.5b) |
| Beneish M = -3.72 (Cap -4..+1) = AAA |
As of June 21, 2026, the stock is trading at USD 79.34 with a total of 22,656,900 shares traded.
Over the past week, the price has changed by -1.23%,
over one month by +0.97%,
over three months by -7.92% and
over the past year by -5.19%.
Medtronic has received a consensus analysts rating of 3.81. Therefore, it is recommended to buy MDT.
- StrongBuy: 12
- Buy: 5
- Hold: 13
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 98 | 23.5% |
P/E Trailing = 21.5496
P/E Forward = 13.4771
P/S = 2.8379
P/B = 2.1067
P/EG = 1.5853
Revenue TTM = 36.4b USD
EBIT TTM = 6.47b USD
EBITDA TTM = 9.43b USD
Long Term Debt = 27.8b USD (from longTermDebt, last quarter)
Short Term Debt = 191.0m USD (from shortTermDebt, last quarter)
Debt = 28.1b USD (from shortLongTermDebtTotal, last quarter) + Leases 58.0m
Net Debt = 27.0b USD (calculated: Debt 28.1b - CCE 1.15b)
Enterprise Value = 130b USD (103b + Debt 28.1b - CCE 1.15b)
Interest Coverage Ratio = 9.04 (Ebit TTM 6.47b / Interest Expense TTM 715.0m)
EV/FCF = 23.99x (Enterprise Value 130b / FCF TTM 5.43b)
FCF Yield = 4.17% (FCF TTM 5.43b / Enterprise Value 130b)
FCF Margin = 14.92% (FCF TTM 5.43b / Revenue TTM 36.4b)
Net Margin = 13.20% (Net Income TTM 4.80b / Revenue TTM 36.4b)
Gross Margin = 65.02% ((Revenue TTM 36.4b - Cost of Revenue TTM 12.7b) / Revenue TTM)
Gross Margin QoQ = 75.86% (prev 64.89%)
Tobins Q-Ratio = 1.42 (Enterprise Value 130b / Total Assets 91.5b)
Interest Expense / Debt = 2.54% (Interest Expense 715.0m / Debt 28.1b)
Taxrate = 21.17% (1.30b / 6.14b)
NOPAT = 5.10b (EBIT 6.47b * (1 - 21.17%))
Current Ratio = 2.54 (Total Current Assets 24.1b / Total Current Liabilities 9.49b)
Debt / Equity = 0.57 (Debt 28.1b / totalStockholderEquity, last quarter 49.0b)
Debt / EBITDA = 2.86 (Net Debt 27.0b / EBITDA 9.43b)
Debt / FCF = 4.97 (Net Debt 27.0b / FCF TTM 5.43b)
Total Stockholder Equity = 48.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.29% (Net Income 4.80b / Total Assets 91.5b)
RoE = 9.92% (Net Income TTM 4.80b / Total Stockholder Equity 48.4b)
RoCE = 8.49% (EBIT 6.47b / Capital Employed (Equity 48.4b + L.T.Debt 27.8b))
RoIC = 6.29% (NOPAT 5.10b / Invested Capital 81.0b)
WACC = 5.64% (E(103b)/V(131b) * Re(6.63%) + D(28.1b)/V(131b) * Rd(2.54%) * (1-Tc(0.21)))
Discount Rate = 6.63% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -24.44 | Cagr: -1.47%
[DCF] Terminal Value 76.04% ; FCFF base≈5.33b ; Y1≈5.56b ; Y5≈6.35b
[DCF] Fair Price = 55.32 (EV 98.0b - Net Debt 27.0b = Equity 71.0b / Shares 1.28b; r=8.35% [WACC [floored]]; 5y FCF grow 4.65% → 2.50% )
EPS Correlation: 76.20 | EPS CAGR: 2.32% | SUE: -0.72 | # QB: 0
Revenue Correlation: 97.27 | Revenue CAGR: 4.84% | SUE: 3.20 | # QB: 4
EPS current Quarter (2026-07-31): EPS=1.39 | Chg30d=+0.52% | Revisions=+18% | Analysts=24
EPS next Quarter (2026-10-31): EPS=1.35 | Chg30d=-5.80% | Revisions=-83% | Analysts=24
EPS current Year (2027-04-30): EPS=5.95 | Chg30d=-1.91% | Revisions=-86% | GrowthEPS=+7.5% | GrowthRev=+6.9%
EPS next Year (2028-04-30): EPS=6.41 | Chg30d=-2.06% | Revisions=-78% | GrowthEPS=+7.7% | GrowthRev=+3.2%
[Analyst] Revisions Ratio: -86%